Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on May 14, 2021. The filing reports a corporate governance event: the election of a new member to the Board of Directors.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the appointment of a director and associated compensation arrangements.
Material Changes
The primary material change reported is the expansion of the Board of Directors from ten to eleven members, effective June 1, 2021, following the election of Dr. Manuel Hidalgo Medina.
Management Commentary and Compensation
Dr. Hidalgo, a medical oncologist with over 20 years of experience in anticancer drug development, was elected to the Board. He is deemed independent under NYSE Listing Standards and will serve on the Science and Technology Committee. His compensation includes:
- An annual retainer of $100,000.
- An annual award of deferred share units valued at $190,000 on the date of grant.
Dr. Hidalgo plans to step down from his role as a paid Scientific Advisory Board member for Agenus upon his election to the Bristol-Myers Squibb Board. No related party transactions were disclosed.
Key Facts for Investor Verification
- Effective date of the new director's term: June 1, 2021.
- New Board size: 11 members.
- Director's specific committee assignment: Science and Technology Committee.
- Total disclosed annual compensation package value: $290,000 (cash and equity).
- Confirmation of independence status under NYSE standards.